2022

Cancer Cell Research (Online ISSN: 2161-2609)

Current Issue

Vol.9 No.36

Article: Autoantibodies to centrosomal protein 70 is expected to become a plasma biomarker forearly diagnosis of female breast cancer

by Yonglong Jin, Yinshi Cui, Lina Dong, Shouguang Wang, Yulong Sheng, Dunmin Zhuang, Bo Li

Cancer Cell Research 2022 9(36) 870-876; published online  30 Decemberr 2022

Abstract: Objective Our previous study found that autoantibodies to tumor associated antigens increased specifically in plasma in the early stage of malignant tumors. This study detected and observed the expression of Cep70 autoantibody in the plasma of patients with breast cancer.Methods The improved and optimized ELISA method was used to detect the expression of Cep70 autoantibody in the plasma of 137 patients with breast cancer and 136 healthy people.Results The SBI value of Cep70 antibody in plasma of tumor group was 1.24±0.48, which was significantly higher than that of control group (1.02±0.15) (P<0.01, t=5.11). Further subgroup analysis showed that there was no significant positive correlation between its expression level and clinical stage (P>0.05). The SBI values of Cep70 antibody in plasma from low-risk group to high-risk group were 1.08±0.59, 1.15±0.26 and 1.33±0.38 respectively. There was significant difference between each group and the control group (P<0.05), and its expression level was also positively correlated with the risk grade. Pearson correlation analysis showed that the expression level of Cep70 antibody in the tumor group was correlated with clinical stage and risk classification (P<0.05), and the risk classification factors were most closely related to the positive rate of Ki67. When the specificity is 90%, the sensitivity is 63%, the yoden index is 0.53, the negative predictive value is 0.83, and the SBI value of Cep70 autoantibody is 1.27 as the cut-off value.Conclusion Cep70 autoantibody is expected to become a plasma biomarker for early diagnosis of female breast cancer.

Open Access Download (free) PDF

Article: Inhibitory effect and mechanism of ‘Taizi Yangrong Decoction’on oral mucositis after radiotherapy for nasopharyngeal carcinoma in vivo and in vitro

by Yonglong Jin, Xiguang Liu, Jing Zhou, Lijie Wang, Shixiang Pan, Haijun Lu

Cancer Cell Research 2022 9(36) 877-885; published online  30 Decemberr 2022

Abstract: Objective: To explore the effect and mechanism of ‘Taizi Yangrong Decoction’on the function of oxidative stress inflammatory response axis after radiotherapy for nasopharyngeal carcinoma. Methods: The rat model of radiation oral mucositis was established.The weight loss rate and behavioral score of rats in each group were observed in vitro;HE staining and immunohistochemistry were observed at the tissue level; At the cell level, the expression changes of oxidative stress and inflammatory factors were observed by ELISA. Results: Compared with the control group, the low-dose and high-dose groups of ‘Taizi Yangrong Decoction’ can improve the weight loss rate and behavior score of rats,and the HE staining and immunohistochemical score decreased significantly.Further in vivo experiments showed that after the intervention of ‘Taizi Yangrong Decoction’, the expression level of oxidative stress related indexes decreased significantly; Similarly,inflammatory factor related indexes the expression level also decreased significantly,and its expression level was closely related to the dosage. Conclusion‘Taizi Yangrong Decoction’ can significantly improve the local mucosal injury and systemic inflammatory response of rats after nasopharyngeal radiotherapy,and the effect of high dose group is the most significant.